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cDepartment of Radiology, University College Cork, National University of Ireland and Cork University Hospital, Cork, IrelandAbstractBackground: Results of previous studies have shown that repeated abdominopelvic computed tomography (CT) examinations can lead to
substantial cumulative diagnostic radiation exposure in patients with Crohn’s disease (CD). Improved selection of patients referred for CT
will reduce unnecessary radiation exposure. This study examines if serum C-reactive protein (CRP) concentration predicts which symp-
tomatic patients with CD are likely to have significant disease activity or disease complications (such as abscess) detected on abdominopelvic
CT.
Methods: All abdominopelvic CTs performed on patients with CD at a tertiary referral centre during the period June 2003 to June 2008 were
identified. CT findings were coded by a pair of independent blinded senior radiologists for (i) small bowel luminal disease, (ii) large bowel
luminal disease, (iii) mesenteric inflammatory changes, (iv) penetrating disease (fistulas, abscess, or phlegmon), (v) acute disease compli-
cations (obstruction or perforation), and (vi) acute non-CD findings. Imaging findings were correlated with serum CRP checked within 14
days before imaging. The reference range for CRP was defined as 0e5 mg/L.
Results: A total of 147 patients with symptomatic CD had a CRP assay performed within 14 days before undergoing abdominopelvic CT.
The median time from CRP assay to imaging was 2 days (interquartile range, 0-6 days). Median CRP before imaging was 24 mg/L
(interquartile range, 6-88 mg/L). CT was normal in 34 of 147 case (23.1%). Patients with normal CRP (n ¼ 36) were significantly less likely
to have penetrating disease (odds ratio [OR], 0.04 [95% confidence interval {CI}, 0.01-0.7]; P < .001) or large bowel luminal disease (OR,
0.3 [95% CI, 0.1-0.8]; P < .05). Normal CRP excluded penetrating disease with a sensitivity of 1.0 (95% CI, 0.87-1.0). CRP levels did not
correlate with the presence of small bowel luminal disease (n ¼ 82), mesenteric inflammatory changes (n ¼ 68), or acute disease
complications (n ¼ 10).
Conclusion: Symptomatic patients with CD and normal serum CRP are unlikely to have evidence of abscess, fistulating disease, or large
bowel luminal disease detected on abdominopelvic CT. However, abdominopelvic CT may demonstrate evidence of clinically significant
non-penetrating CD or complications, including perforation and acute obstruction, regardless of serum CRP concentration.ResumeContexte : Des etudes anterieures ont demontre que les tomodensitometries abdominopelviennes a repetition peuvent causer une importante
exposition cumulee a la radiation dans le but de diagnostic chez les patients souffrant de la maladie de Crohn. Une meilleure selection des
patients orientes en tomodensitometrie contribuera a reduire les expositions inutiles aux radiations. Cette etude examine si la concentration de* Address for correspondence:MichaelM.Maher, MD, FRCR, FFR(RCSI),
Alimentary Pharmabiotic Centre, University College Cork, National Univer-
sity of Ireland, Cork, Ireland.
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268 A. N. Desmond et al. / Canadian Association of Radiologists Journal 63 (2012) 267e274proteine C-reactive serique permet de predire pour quels patients symptomatiques souffrant de la maladie de Crohn une TDM abdomi-
nopelvienne est la plus susceptible de detecter une activite marquee de la maladie ou des complications (comme un abces).
Methodes : Toutes les tomodensitometries abdominopelviennes effectuees sur des patients souffrant de la maladie de Crohn entre juin 2003
et juin 2008 dans un centre de soins tertiaires ont ete selectionnees. Deux radiologistes principaux independants ont code a l’aveugle les
resultats des examens afin de deceler : (i) les pathologies luminales de l’intestin gre^le, (ii) les pathologies luminales du gros intestin, (iii) les
changements relatifs a l’inflammation mesenterique, (iv) les pathologies penetrantes (fistules, abces ou phlegmon), (v) les complications de
pathologies aigu€es (obstruction ou perforation) et (vi) les constatations aigu€es non liees a la maladie de Crohn. Les resultats des examens ont
ete mis en correlation avec la concentration de proteine C-reactive serique mesuree dans les 14 jours precedant l’examen. L’intervalle de
reference de la proteine C-reactive etait de 0 a 5 mg/L.
Resultats : Le dosage de la proteine C-reactive a ete effectue sur un total de 147 patients symptomatiques souffrant de la maladie de Crohn
dans les 14 jours precedant la TDM abdominopelvienne. Le delai moyen entre le dosage et l’examen etait de deux jours (ecart interquartile de
0 a 6 jours). La concentration moyenne de proteine C-reactive serique avant l’examen etait de 24 mg/L (ecart interquartile de 6 a 88 mg/L).
Le resultat de la TDM etait normal dans 34 des 147 cas (23,1%). Les patients affichant un taux de proteine C-reactive normal (n ¼ 36) etaient
beaucoup moins susceptibles de presenter une pathologie penetrante (rapport de cotes de 0,04 [intervalle de confiance de 95%, de 0,01 a 0,7];
P < 0,001) ou une pathologie luminale du gros intestin (rapport de cote de 0,3 [intervalle de confiance de 95%, de 0,1 a 0,8]; P < 0,05). Un
taux normal de proteine C-reactive serique excluait les pathologies penetrantes avec une sensibilite de 1,0 (intervalle de confiance de 95%,
0,87 a 1,0). Les niveaux de proteine C-reactive ne correlaient pas avec la presence d’une pathologie luminale de l’intestin gre^le (n ¼ 82), de
changements relatifs a l’inflammation mesenterique (n ¼ 68) ou des complications d’une pathologie aigu€e (n ¼ 10).
Conclusion : Les patients symptomatiques souffrant de la maladie de Crohn dont le taux de proteine C-reactive serique est normal sont peu
susceptibles de presenter des signes d’abces, de fistules ou de pathologie luminale du gros intestin lors d’une TDM abdominopelvienne. Une
TDM abdominopelvienne peut toutefois reveler l’existence cliniquement significative de la maladie de Crohn non penetrante ou de
complications, y compris des perforations ou obstructions aigu€es, peu importe la concentration de proteine C-reactive serique.
 2012 Canadian Association of Radiologists. All rights reserved.
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reactive protein (CRP) are both routinely used in the
assessment of patients with Crohn’s disease (CD) [1].
Whereas the European Crohn’s and Colitis Organisation
recognizes abdominopelvic CT as an ‘‘important additional
diagnostic tool’’ that complements clinical impression and
endoscopic assessment, there are no specific guidelines for
when cross-sectional imaging should be performed.
When assessing a patient with CD and significant
symptoms, the clinician must answer the following question:
does this patient have (i) active luminal disease and/or
uncomplicated fistulating disease, (ii) extraluminal compli-
cations such a Crohn’s mass or an abscess, (iii) a coexisting
or unforeseen comorbidity, or (iv) no active disease
processes. In the new era of therapeutics, when immune-
modulating and immunosuppressing drugs are often
prescribed as first-line treatments for active CD, the stakes
for patients are high. Patients with significant symptoms due
to active luminal inflammation are likely to achieve remis-
sion with high-dose steroids and/or the introduction of antie
tumour necrosis factor drugs or immunosuppressants.
However, patients with abdominal or pelvic abscesses
require appropriate antibiotics plus radiologically guided or
surgical drainage when appropriate and are at increased risk
of significant septic complications if inappropriately
immunosuppressed. Patients with other intra-abdominal
processes, such as gallstones or diverticulitis, require
specific non-CD directed therapies and may also be at
increased risk of septic complications if prescribed potent
immune-modifying drugs. Patients without clinical, endo-
scopic, or radiographic evidence of CD activity are likely torequire reassessment and may respond to less aggressive
treatment strategies.
Due to its widespread availability and established diag-
nostic performance in CD, symptomatic patients frequently
undergo abdominopelvic CT imaging and are consequently
exposed to significantly more diagnostic radiation than
patients with other forms of inflammatory bowel disease.
Results of previous studies have demonstrated that patients
with CD are at risk of substantial and potentially excessive
cumulative exposure to ionizing radiation attributable to
diagnostic imaging, primarily due to abdominopelvic CT
imaging [2e4]. Excess radiation exposure may be of
particular concern for patients with CD, who already carry an
increased lifetime risk of developing gastrointestinal malig-
nancies. Alternative imaging modalities, including ultra-
sound and magnetic resonance imaging (MRI), do not
employ ionizing radiation and have established efficacy in
the investigation of patients with CD.
Serum CRP is a biochemical marker of inflammation,
which has previously been shown to correlate well with CD
endoscopic severity, histologic findings, and clinical scores
of disease activity [5e9]. CRP levels are routinely used to
monitor patients with CD and to inform therapeutic strate-
gies, including the prescription of corticosteroids, immuno-
suppressants, and biologic drugs [10,11]. In this study, we
investigate if serum CRP level predicts which symptomatic
patients with CD who are undergoing abdominopelvic CT
will have a normal imaging study and which patients will
have significant disease activity or extraluminal complica-
tions detected. Our goal is to improve the selection of
patients with CD who are referred for abdominopelvic CT
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in this patient group.
MethodsPatient PopulationAfter institutional review board approval, individuals with
CD were identified from the patient database of a tertiary
referral centre for inflammatory bowel disease. All abdomi-
nopelvic CT studies performed in the period June 2003 to
June 2008 were retrospectively identified by cross-
referencing patient details with the institution’s centralized
electronic imaging records. Abdominopelvic CT studies
were included if a serum CRP assay had been performed
within 14 days before imaging. In all cases, serum CRP had
been measured by the centre’s on-site diagnostic laboratory
by using an anti-CRP antibody assay (Olympus Life
Sciences Europa, Hamburg, Germany). Normal serum CRP
concentration was defined as less than 5 mg/L.Abdominopelvic CT TechniqueIn all cases, abdominopelvic CT imaging was performed
by using a 4-slice multidetector row Toshiba Aquilion
(Toshiba Corp, Tokyo, Japan) CT scanner or a single-
detector Siemens Somatom (Siemens Corp, Munich,
Germany) CT scanner. Imaging was performed from the lung
bases to the symphysis pubis according to standard protocols.
Beam collimation was 4 mm by 3 mm for multidetector
studies and 1 mm by 8 mm for single-detector studies. All
studies used a tube potential of 120 kVand fixed tube current
was varied according to patient body habitus. All the patients
were given oral contrast 1-2 hours before imaging (1-1.5 L of
a 2% solution of Gastrograffn [Bracco Diagnostics, Prince-
ton, NJ]) and administered 100 mL of low osmolar, non-
iodinated intravenous contrast (Niopam 300, 61.22% w/v
Iopamidol, iodine 300 mg/mL; Bracco UK Ltd, Bucks, UK).
Images were acquired in the portal venous phase 70 seconds
after intravenous contrast administration.
Abdominopelvic CT findings were reviewed indepen-
dently by 2 investigators who were blinded to CRP levels.
Studies were coded for the following types of positive
finding: (i) small bowel luminal disease (wall thickening and/
or hyperenhancement, strictures without obstruction, and
strictures with obstruction), (ii) large bowel luminal disease
(classified as per small bowel luminal disease), (iii) mesen-
teric inflammatory changes (mesenteric stranding, hyper-
vascularity, or lymphadenopathy), (iv) penetrating disease
(fistulas, phlegmon, or abscess), and (v) acute disease
complications (acute bowel obstruction, ileus, or perfora-
tion). Acute non-CD findings also were coded (eg, pneu-
monia and acute diverticulitis). We did not attempt to score
for evidence of upper gastrointestinal CD or perianal CD,
because CT has a low sensitivity for both findings. Positive
findings were coded according to the contemporaneous
findings of the reporting consultant radiologist.Data Collection and Statistical AnalysisData entry and statistical analyses were performed by
using Microsoft Access (Microsoft Corp, Redmond, WA)
and GraphPad Prism version 5.01 (GraphPad Software
Incorporated, San Diego, CA), respectively. Correlations
between CRP and imaging scores were analysed by the
Pearson analysis or the Spearman analysis, as appropriate.
The differences in CRP concentrations among groups of
patients were analysed by the Mann-Whitney U test or
Kruskall-Wallis test, as appropriate. Odds ratios (OR) for
positive findings were calculated by using the Fisher exact
test. The sensitivity and specificity of normal CRP and of
CRP in the upper quartile for the patient population were
assessed by standard receiver operator curve analysis.Results
In the period June 2003 to June 2008, a total of 442
abdominopelvic CTs were performed on patients with CD.
Imaging records and laboratory results were available in all
cases. CRP had been checked within 14 days before
imaging in 159 of 442 cases (36%). To eliminate double
sampling, we excluded repeated CTs performed on the same
patient within 14 days (n ¼ 12). The remaining 147 CTs
comprised the study cohort. The 147 studies had been per-
formed on 89 patients (38 men, 51 women; mean age 37.2
years; age range, 16e84.4 years; and median, 1 CT per
patient; range, 1e8 CTs). The median interval from CRP
assay to imaging was 2 days (range, 0-14 days). Median
CRP concentration before imaging was 24 mg/L (range,
0-500 mg/L). CRP was normal (<5 mg/L) in 24.5% of cases
(36/147). The upper quartile for serum CRP before imaging
was 89 mg/L.Abdominopelvic CT FindingsThe frequencies of positive abdominopelvic CT findings
are shown in Figure 1. Almost a quarter of studies (23.1%, n
¼ 34) showed no radiographic evidence of CD. Small bowel
luminal disease was the most common finding, evident on
55.7% (n ¼ 82) of studies. The majority of these cases (n ¼
77) had uncomplicated small bowel wall thickening or
hyperenhancement, without strictures or obstruction. Large
bowel luminal disease was less common, seen in 29.9% of
studies (n ¼ 44). Large bowel strictures were an uncommon
CT finding, evident in only 2.7% of studies (n ¼ 4). Pene-
trating disease (CD fistulas, phlegmon and/or inflammatory
mass, or abscess) was present in 18.3% of cases (n ¼ 27).
Acute disease complications were present on 6.8% of
abdominopelvic CTs (n ¼ 10) (6 cases of acute bowel
obstruction, 3 cases of perforation, and 1 study with both
acute obstruction and perforation). Acute disease processes
not directly related to CD were evident on 9.5% of studies
(n ¼ 14), the most common being basal pneumonia (n ¼ 6)
(see Table 1).
Figure 1. Distribution of abdominopelvic computed tomography findings in symptomatic patients with Crohn’s disease. Overall 34 of 147 studies (23.1%)
showed no evidence of Crohn’s disease activity.
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CT FindingsMedian CRP concentrations in patients with and without
CT findings are shown in Table 2. CRP levels were not
significantly higher in patients with CT evidence of small
bowel luminal disease or patients with visible mesenteric
inflammatory changes. CRP was elevated in patients with
penetrating disease and was significantly higher in patients
with an abscess than in patients without an abscess (median
CRP, 63 mg/L vs 23 mg/L; P ¼ .03). Serum CRP also was
significantly higher in the 14 patients with acute non-CD
pathologies demonstrated on abdominopelvic CT (median
CRP, 60.5 mg/L vs 22 mg/L; P < .05). There was only 1 case
of simultaneous acute non-CD finding and penetrating
disease (left basal pneumonia in a patient with an ileocuta-
neous fistula). Serum CRP levels were modestly elevated inTable 1
Abdominopelvic computed tomography in symptomatic patients with
Crohn’s disease: frequency of acute non-Crohn’s disease findingsa
Finding
Frequency
N %
Basal pneumonia 6 4.1
Appendicitis 1 0.7
Cholecystitis 1 0.7
Diverticulitis 1 0.7
Small bowel intussusception 1 0.7
Small bowel lymphoma 1 0.7
Pancreatitis 1 0.7
Pyelonephritis 1 0.7
Sacroiliitis 1 0.7
Total 14 9.5
a Total N ¼ 147 computed tomographies were performed on 89 patients.patients with acute perforation or acute bowel obstruction
(median CRP, 55.5 mg/L; IQR, 12-84.5 mg/L).Predictive Value of Normal CRPAbdominopelvic CTs performed on patients with CRP
within the reference range (<5 mg/L) were more likely to be
normal (OR, 2.9 [95% CI, 1.3-6.6]; P ¼ .01) and showed no
radiographic evidence of CD in 14 of 36 cases (Table 3).
Patients with CRP < 5 mg/L were significantly less likely to
have fistulating disease or an abscess on abdominopelvic CT
(OR, 0.05 [95% CI, 0.01-0.8]; P < .005). CRP in the normal
range excluded penetrating disease with a sensitivity of 1.0
(95% CI, 0.87-1.0) (Table 4). Normal CRP also indicated
a decreased likelihood of large bowel luminal disease (OR,
0.3 [95% CI, 0.8-0.8]; P < .05) and excluded acute non-CD
findings, with a sensitivity of 0.93 (95% CI, 0.66-0.99).
Although serum CRP elevated above the normal range pre-
dicted penetrating disease with a specificity of 0.80 (95% CI,
0.71-0.88), it was not a reliable predictor of other positive
findings on CT, with a specificity of 0.20 for acute disease
complications (95% CI, 0.03-0.56) and specificity of
between 0.29 and 0.31 for all other CD findings (Figure 2).Predictive Value of CRP in the Upper QuartilePatients with CRP in the upper quartile (89 mg/L) were
significantly more likely to have evidence of abscess or fistu-
lating CD on abdominopelvic CT (OR, 3.0 [95% CI, 1.2-7.5]:
P < .05) (Table 3). Serum CRP > 89 mg/L predicted the
presence of penetrating disease, with a specificity of 0.80 (95%
CI, 0.72-0.87) (Figure 3 andTable 5). CRP concentration in the
upper quartile for the population did not increase the likelihood
of other types of positive findings on abdominopelvic CT and
Table 2
Serum CRP (mg/L) and abdominopelvic CT findings in symptomatic patients with Crohn’s disease (N ¼ 147)
Finding present Finding absent
n Median CRP IQR n Median CRP IQR P valuea
CT evidence of Crohn’s disease 113 29.0 7.0-87.0 34 16.5 0-108.8 .31
Small bowel luminal disease 82 24 6.8-75.5 65 25 0-105 .92
Wall thickening and/or hyperenhancement 77 22 6.0-76.0 70 33.5 0-103.5 .74
Strictures without obstruction 7 45 7.0-56.0 140 24 1.5-94.8 .83
Strictures with obstruction 16 44.5 10.8-201.5 131 23 0- 86 .25
Large bowel luminal disease 44 33 11-94.3 103 22 0-88 .26
Wall thickening and/or hyperenhancement 44 33 11-94.3 103 22 0-88 .26
Strictures without obstruction 2 152.5 0-305 145 24 6-87 db
Strictures with obstruction 2 45.5 25-66 145 24 3-92.5 db
Penetrating disease 27 63 22-167 120 20 0-73.8 .001
Fistulating disease 14 51 19.5-150 133 23 0-83.5 .08
Abscess 15 63 11-195 132 23 0-80 .03
Phlegmon 4 62.5 37-138.3 143 23 0-86 .24
Mesenteric inflammatory changes 68 24 7-98.5 79 25 0-86 .65
Fat stranding 57 24 6.5-91.5 90 24 0-90.3 .74
Hypervascularity 5 20 11-139 142 25 0-86.5 .68
Lymphadenopathy 26 34.5 13.5-148.3 121 24 0-83.5 .28
Acute complications 10 55.5 12-84.5 137 24 3-92.5 .82
Perforation 4 68.5 28.5-11.5 143 24 0-88 .33
Acute obstruction 7 48 0-66 140 24 6-94.8 .97
Acute non-Crohn’s disease findings 14 60.5 34-108.8 133 22 0-87 <.05
CRP ¼ C-reactive protein; CT ¼ computed tomography; IQR ¼ interquartile range.
a Kruskall-Wallis test.
b Insufficient positive large bowel findings.
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mesenteric inflammatory changes, and acute non-CD findings.
Acute disease complications (acute obstruction and acute
perforation)were notmore likely in patientswithCRP levels in
the upper quartile.Table 3
OR of CT findings in symptomatic patients with Crohn’s disease and CRP in no
CRP in normal range (<5 m
n ¼ 36
N OR 95
Normal abdominopelvic CT 14 2.9 1.
Small bowel luminal disease 16 0.6 0.
Wall thickening and/or hyperenhancement 16 0.7 0.
Strictures without obstruction 1 0.5 0.
Strictures with obstruction 3 0.7 0.
Large bowel luminal disease 5 0.3 0.
Wall thickening and/or hyperenhancement 4 0.3 0.
Strictures without obstruction 1 3.1 0.
Strictures with obstruction 0 0.6 0.
Penetrating disease 0 0.04 0.
Fistulating disease 0 0.1 0.
Abscess 0 0.1 0.
Phlegmon 0 0.3 0.
Fistulating disease or abscess 0 0.05 0.
Mesenteric inflammatory changes 13 0.6 0.
Fat stranding 11 0.6 0.
Hypervascularity 0 0.3 0.
Lymphadenopathy 4 0.3 0.
Acute disease complicationsb 2 0.8 0.
Acute non-Crohn’s disease findings 1 0.2 0.
CI ¼ confidence interval; CRP ¼ C-reactive protein; CT ¼ computed tomograp
a Total N ¼ 147 abdominal CTs in 89 patients with Crohn’s disease.
b Acute bowel obstruction or perforation.Discussion
This study shows that, among symptomatic patients with
CD referred for abdominopelvic CT, imaging is more likely
to be normal in those with normal CRP concentrations and isrmal range and CRP in upper quartilea
g/L),
P
CRP in upper quartile
(>89 mg/L), n ¼ 35
P% CI N OR 95% CI
3-6.6 .01 9 1.1 0.4-2.8 .82
2-1.2 .13 17 0.6 0.3-1.3 .25
3-1.4 .36 16 0.7 0.3-1.4 .34
1-4.3 1.00 1 0.5 0.06-4.3 1.00
06-2.6 .76 5 1.5 0.5-4.5 .54
1-0.8 <.05 9 1.0 0.5-2.4 1.00
1-0.8 <.05 9 1.0 0.5-2.4 1.00
1-52 .43 1 3.1 0.2-52 .43
1-13 .60 0 0.6 0.03-13 1.00
01-0.7 <.001 12 3.0 1.2-7.1 <.05
01-1.6 <.05 5 1.8 0.6-5.9 .33
01-1.5 .12 7 2.7 1.1-8 .06
02-6.2 .57 1 1.0 0.1-10 1.00
01-0.8 <.005 25 3.0 1.2-7.5 <.05
3-1.2 .18 17 1.1 0.5-2.2 1.00
3-1.4 .33 14 1.0 0.5-2.2 1.00
01-4.9 .34 2 2.1 0.4-13.2 .59
2-1.6 .32 7 1.2 0.5-3.1 .80
2-3.7 1.00 1 0.8 0.2-3.7 1.00
03-1.7 .19 4 1.3 0.4-4.3 .74
hy; OR ¼ odds ratio.
Table 4
Abdominopelvic CT findings in symptomatic patients with Crohn’s disease: sensitivity and specificity of normal CRP (<5 mg/L)a
CRP < 5 mg/L Sensitivity 95% CI Specificity 95% CI
Any CT evidence of Crohn’s disease 0.81 0.73-0.88 0.43 0.26-0.61
Small bowel luminal disease 0.81 0.70-0.88 0.31 0.20-0.44
Large bowel luminal disease 0.89 0.75-0.96 0.30 0.22-0.40
Mesenteric inflammatory changes 0.81 0.70-0.89 0.29 0.19-0.40
Penetrating disease 1.00 0.87-1.00 0.80 0.71-0.88
Acute disease complicationsb 0.80 0.44-0.98 0.20 0.03-0.56
Acute non-Crohn’s disease findings 0.93 0.66-0.99 0.31 0.23-0.39
CI ¼ confidence interval; CRP ¼ C-reactive protein; CT ¼ computed tomography.
a Total N ¼ 147 CTs performed on 89 patients with Crohn’s disease; the median time from CRP assay to CT was 2 days.
b Acute bowel obstruction, n ¼ 7; perforation, n ¼ 4.
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fistulating disease, or large bowel luminal disease. These
findings may be useful in clinical scenarios in which cross-
sectional imaging is considered to exclude penetrating
disease, for example, before the prescription of steroids or
other immunosuppressants, and in symptomatic patients in
whom full colonoscopy has been declined or proven tech-
nically difficult. Given the potential for serious septic
complications of immune-suppressing therapies, abdomi-
nopelvic CT should be considered to rule out abscess or
active fistulating disease in symptomatic patients with CRP
levels in the upper quartile. However, because CRP elevation
is a poor predictor of nonpenetrating disease activity on CT,
high CRP levels alone should not guide the decision to
perform diagnostic imaging in patients in whom penetrating
disease is not anticipated.
In the acutely unwell patient with CD, abdominopelvic
CT is often the investigation of choice to rule out an acute
disease complication, such as perforation or acute obstruc-
tion. Analysis of our data shows that such acute disease
complications are associated with modest elevations of
serum CRP and cannot be excluded by CRP in the normal
range. Therefore, serum CRP concentration should not
influence the decision to perform abdominopelvic CT
imaging in patients in whom such serious acute complica-
tions are suspected.
The high rates of detection of small bowel luminal disease
and mesenteric inflammatory changes suggest that many
patients are being referred appropriately for abdominopelvic
CT and that imaging findings are likely to influence clinicalTable 5
Abdominopelvic CT findings in symptomatic patients with Crohn’s disease: sen
CRP > 89 mg/L Sensitivity
Any CT evidence of Crohn’s disease 0.25
Small bowel luminal disease 0.22
Large bowel luminal disease 0.25
Mesenteric inflammatory changes 0.27
Penetrating disease 0.46
Acute disease complicationsb 0.20
Acute non-Crohn’s disease findings 0.29
CT ¼ computed tomography; CRP ¼ C-reactive protein; CI ¼ confidence inter
a Total N ¼ 147 CT scans performed with 89 patients with Crohn’s disease; m
b Acute bowel obstruction, n ¼ 7; perforation, n ¼ 4.decision making. Given that penetrating disease is less likely
in patients with symptomatic CD with normal CRP, radiol-
ogists may wish to consider CT enterography or MR enter-
ography in this patient subgroup [1]. CT enterography is
performed with negative oral contrast, which provides
adequate luminal distension and characterizes non-
penetrating mucosal inflammation and strictures with greater
precision than conventional abdominopelvic CT [12,13].
Abdominopelvic CT imaging is often performed to rule
out non-CD pathologies or unanticipated disease comorbid-
ities, including malignancy. This study shows that such
conditions are present on almost 10% of imaging studies
performed in symptomatic patients with CD. Whereas,
findings such as pneumonia and acute gastrointestinal
pathologies, including pancreatitis and diverticulitis, are
associated with modest elevations in serum CRP, their
presence is not excluded by normal CRP or predicted by
CRP in the upper quartile.
This study demonstrates that serum CRP does not corre-
late with radiographic evidence of mesenteric inflammatory
changes or nonpenetrating small bowel luminal disease in
symptomatic patients with CD. The fact that luminal
inflammation is not necessarily associated with significant
rises in serum CRP is consistent with previous studies and
although alternative and more-sensitive markers of luminal
inflammation have been proposed, none are currently in
widespread clinical use.
AbdominopelvicCTmakes an important contribution to the
optimal management of many patients with CD. As well as
defining the severity of luminal disease and stenotic lesions,sitivity and specificity of CRP in the upper quartile (>89 mg/L)a
95% CI Specificity 95% CI
0.17-0.34 0.74 0.57-0.88
0.14-0.33 0.71 0.58-0.81
0.13-0.40 0.75 0.65-0.83
0.17-0.39 0.76 0.65-0.85
0.28-0.66 0.80 0.72-0.87
0.03-0.56 0.80 0.44-0.98
0.08-0.58 0.75 0.67-0.82
val.
edian time from CRP assay to CT was 2 days.
Figure 2. Contrast-enhanced computed tomography of the abdomen in a 28-
year-old man with Crohn’s disease, demonstrating thickened loops of small
bowel (arrowheads) without evidence of penetrating disease. Serum C-
reactive protein before imaging was less than 5 mg/dL.
Figure 3. Contrast-enhanced computed tomography of the abdomen in a 33-
year-old woman with Crohn’s disease. An abdominal-wall abscess with
associated locules of gas and stranding of the subcutaneous fat is evident
(arrow). A thickened loop of small bowel is intimately related to the anterior
abdominal wall (arrowhead), which suggests fistula formation. Serum C-
reactive protein before imaging was 145 mg/dL.
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changes and penetrating CD activity [12,14e17]. Diagnostic
performance coupled with widespread availability means that
patients with CD are often referred for numerous abdomi-
nopelvic CT studies [2]. Many clinicians have poor knowledge
of the effective dose of ionizing radiation incurred by imaging
studies and may not be aware that an abdominopelvic CT
delivers an effective dose of approximately 10 milli-Sieverts
(mSv) of ionizing radiation, equivalent to 14 plain abdominal
films (at 0.7 mSv each) or 500 chest radiographs (at 0.02 mSv
each). Although MR imaging and ultrasound (which do not
incur diagnostic radiation exposure) both have proven diag-
nostic utility in CD, both are also subject to restrictions [18].
MR imaging often has limited accessibility and involves
increased cost, increased acquisition time, and patient
discomfort due to claustrophobia. Abdominal ultrasound is
time consuming and its overall diagnostic performance in CD
is operator dependant. However, although neitherMR imaging
nor ultrasound is likely to replace abdominopelvic CT in the
near future, results of recent studies have demonstrated
a rapidly increasing role of MR imaging in this group of
patients [19e21].
Results of recent studies have demonstrated that up to
16% of patients with CD and attending specialist centres are
exposed to potentially excessive levels of diagnostic radia-
tion, largely due to abdominopelvic CT imaging [2].
Because CD often presents in early adulthood and is asso-
ciated with an increased lifetime risk of gastrointestinal
neoplasia, clinicians should employ diagnostic ionizing
radiation only when the information provided is likely to
influence management. The findings of this study show that
normal CRP levels indicate a significantly reduced risk of
abscess, fistulating disease or large bowel luminal disease,
and suggest that abdominopelvic CT may be deferred with
a very low likelihood of an adverse outcome in selected
patients.
It is important to note that, within the realmofCTin patients
withCD, there is scope for achieving diagnostic quality images
with a significantly lower radiation dose by a variety of
methods [22]. Automatic tube current modulation, noisereduction filters, and automatic exposure control all success-
fully allow a reduction in radiation exposure. Novel iterative
reconstruction techniques also have demonstrated the poten-
tial for improved image quality and reduced radiation dose in
CT [22].
This study is subject to limitations. The patients with CD
included those who were attending a tertiary referral
inflammatory bowel disease centre and, therefore, represent
patients at the more severe end of the disease spectrum.
Whereas, patient data are gathered prospectively by the
study institution, the information used for this study was
analysed retrospectively and limited to the dates covered by
the detailed patient database. The use of single-slice and
4-slice CT technology has now been almost universally
replaced by mutidetector CT (MDCT). MDCT employs up
to 64 or 128 detectors and has greater sensitivity and
specificity for fistulating disease and abscesses [23].
Although fistulating disease was present in almost 1 in 10 of
the patients included in this study, it was absent in all 36
patients with serum CRP in the normal range. Use of newer
techniques may have resulted in detection of minor degrees
of penetrating disease in some of these patients. Further
research should include analysis of the value of CRP esti-
mation in conjunction with these newer imaging techniques.
The exclusion of a significant proportion of patients under-
going CT, due to a lack of a recent CRP measurement, is
a potential source of bias. CT findings were coded based on
contemporaneous scan interpretation rather than direct
reevaluation of the CT images.
In symptomatic patients with CD, the CRP level alone
does not predict the presence of clinically significant non-
penetrating disease activity or acute disease complications on
abdominopelvic CT. However, normal CRP is a useful
diagnostic test for excluding the presence of abscess, fistu-
lating disease, and large bowel luminal disease in symp-
tomatic patients with CD and may allow clinicians to
improve the selection of patients who are referred for
abdominopelvic CT.
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